Loading...

PODCAST

The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week"s biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts,

science life sciences

All Episodes

00:13:05

May 03, 2026 | UCB's $2.2B Candid Therapeutics Deal;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/05/04

UCB drops $2B upfront for Candid Therapeutics' autoimmune T-cell engager cizutamig — their second billion-dollar deal in three weeks. FDA proposes withdrawing Amgen's Tavneos over data manipulation allegations. Pfizer/Arvinas' Veppanubecomes the first approved PROTAC degraderVisit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, UCB, Candid vTherapeutics, cizutamig, autoimmune, T-cell

en-us

00:10:27

May 01, 2026 | FDA Approves First PROTAC Drug...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/05/04

FDA clears Veppanu, the first protein degrader to reachmarket — but no commercial partner in sight. Q1 biopharma M&A hits $84B as patent cliff urgency drives a mega year. Plus: Truqap wins 7-1 ODAC vote in prostate cancer, Auvelity expands into Alzheimer's agitation, and Summit's ivonescimab stumbles before ASCO.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Veppanu,vepdegestrant,

en-us

00:10:07

Apr 28, 2026 | Erasca Crashes 48% on Patient Death;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/29

Erasca loses half its market cap after a Phase 1 death —while AbbVie bets $1.45B on the same RAS target. Lilly acquires Ajax for $2.3B in its 5th deal of 2026; FDA alleges data manipulation behind Amgen's Tavneos; Boehringer survodutide hits 16.6% weight loss in Phase 3.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Erasca, ERAS-0015, pan-RAS, KRAS, AbbVie, Kestrel Therapeutics, Eli

en-us

00:10:36

Apr 27, 2026 | Sun Pharma just wrote an...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/28

Sun Pharma just wrote an eleven-point-seven-five billiondollar check to acquire Organon — the largest outbound pharma acquisition in Indian history, according to Reuters. And Intellia's in vivo CRISPR therapyjust delivered the first Phase 3 win for gene editing inside the body. Big Monday. Let's get into it.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Eli Lilly, Lilly,

en-us

00:10:26

Apr 24, 2026 | Foundayo Trails Oral Wegovy 5-to-1 in...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/25

Lilly's Foundayo logs just 3,707 prescriptions in week two vs. 18,410 for Novo's oral Wegovy — a 5:1 gap that sent Lilly stock tumbling. Inhibrx surges ~39% on Merck-led takeover interest at $53/share. EU backs Sanofi's tolebrutinib for MS despite FDA rejection. FDA issues psychedelics priority review vouchers.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Foundayo, orforglipron, Eli Lilly,

en-us

00:09:26

Apr 23, 2026 | Regeneron's Otarmeni Approved as First...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/24

FDA approves Regeneron's Otarmeni — the first gene therapy for genetic hearing loss — as Regeneron closes the 17th and final White House MFN pricing deal. Roche calls giredestrant its potentially largest product ever, Novo Nordisk's 72% decline deepens, AbbVie commits $1.4B to North Carolina.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Regeneron, Otarmeni, gene therapy, hearing loss, FDA

en-us

00:10:04

Apr 21, 2026 | Merck Welireg Fails First-Line Kidney...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/22

Merck's Welireg misses in first-line RCC — Cantor challenges $2B+ peak sales. Lilly buys Kelonia for up to $7B in in vivo CAR-T push. Medicare indefinitely delays GLP-1 weight loss drug coverage pilot. Plus AstraZeneca IgAN data, Roche MOGAD results, Arrowhead upgrade.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Merck, Welireg, belzutifan, kidney cancer, renal cell carcinoma, Keytruda,

en-us

00:10:26

Apr 20, 2026 | Lilly's $7B Kelonia In Vivo CAR-T Bet;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/21

Eli Lilly pays $3.25B upfront for Kelonia Therapeutics' invivo CAR-T platform in a deal worth up to $7B — the sixth buyout in this space since March 2025. Plus Gilead-Arcus TIGIT Phase 3 failure, Nektar's 20%+ alopecia surge, Trump's psychedelic executive order, AACR KRAS data from Revolution Medicines, and Novo Nordisk sickle cell Phase 3 results.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The

en-us

00:13:27

Apr 19, 2026 | Allogene's Off-the-Shelf CAR-T Clears...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/21

Allogene's cema-cel drives MRD negativity in 7 of 12lymphoma patients in Phase 3 Alpha3 — stock surges 50%+. Plus: Kailera's $625M biotech IPO, UCB's $1.2B Neurona acquisition for epilepsy cell therapy, Spyre'sbest-in-class UC data, Lilly Foundayo's launch metrics, and what to watch as AACR and Q1 earnings collide this week.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout,

en-us

00:09:10

Apr 16, 2026 | Lilly Foundayo Clears Heart Safety for...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/17

Foundayo hits MACE-4 non-inferiority (HR 0.84) as Lillytargets diabetes filing by Q2 — but FDA requests liver risk data. Plus: Cochrane review dismisses anti-amyloid Alzheimer's drugs, Daiichi Sankyo divests $1.5B consumer health unit, and Kailera's $533M obesity IPO pricesahead of tomorrow's trading.visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Foundayo,orforglipron, Eli Lilly,

en-us

00:09:41

Apr 15, 2026 | J&J Q1 Earnings Beat on Tremfya...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/16

J&J's Tremfya hits $1.6B in Q1 sales with 74% growth,answering the Stelara biosimilar cliff. Plus: Revolution Medicines prices a $2B offering, Beeline launches with $300M and five BMS immunology assets, and Travere wins the first FDA approval for FSGS.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Johnson &Johnson, Tremfya, Stelara, Revolution Medicines, Beeline Medicines,

en-us

00:10:21

Apr 14, 2026 | Daraxonrasib Nearly Doubles Pancreatic...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/14

Daraxonrasib slashes death risk 60% in metastatic pancreaticcancer Phase 3 — Revolution Medicines leads a $1.5B offering wave. Neurocrine acquires Soleno for $2.9B, Regeneron enters radiopharma via Telix, and Travere nabs the first-ever FSGS approval with Filspari.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, daraxonrasib, Revolution Medicines, RVMD, pancreatic cancer, RASolute 302,

en-us

00:14:08

Apr 12, 2026 | FDA Rejects Replimune RP1 Again; Sun...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/13

FDA issues second CRL for Replimune's melanoma therapy RP1 —stock drops 20%, single-arm trial debate sharpens. Sun Pharma's $12B all-cash bid for Organon, Amgen's 77% proptosis response in subcutaneous TEPEZZA Phase 3, Lilly launches Foundayo, and AACR 2026 preview.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Replimune, RP1,vusolimogene oderparepvec, melanoma, complete response

en-us

00:10:44

Apr 09, 2026 | Lilly Launches Oral GLP-1 Foundayo;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/09

Lilly launches Foundayo to challenge Novo Nordisk in oralGLP-1s with a GoodRx access play. Gilead acquires ADC specialist Tubulis for $3.15B upfront in its third deal since February. Plus FDA lifts MacroGenics hold, AbbVie sues over 340B, and Vanda targets GLP-1 side effects with theThetis trial.www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, Foundayo, oral GLP-1, Novo Nordisk, Gilead Sciences,

en-us

00:09:58

Apr 07, 2026 | Pharma Tariffs Hit 100% with Major...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/08

100% tariffs on branded drug imports took effect — but thecarve-outs may matter more than the rate. Gilead acquires ADC maker Tubulis for $3.15B upfront (up to $5B), Merck launches its $6B Terns tender offer after cutting the bid by $1B on data concerns, and Novo Nordisk rolls out Wegovy HD7.2mg nationwide. Plus FDA Commissioner Makary's FY2027 budget proposals and Corbus secures its CRB-701 registration path.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials,

en-us

00:09:31

Apr 06, 2026 | Gilead's $3.15B Tubulis ADC Deal;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/08

Gilead pays $3.15B for ADC specialist Tubulis — third dealin six weeks. Neurocrine bets $2.9B on Soleno for Prader-Willi, Merck reprices Terns by $1B after data peek, and Sanofi's bispecific lunsekimig hits in asthma but misses in eczema. Plus Novo launches high-dose Wegovy.www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Gilead, Tubulis, ADC, antibody-drug conjugate, Neurocrine, Soleno, Prader-Willi,

en-us

00:13:40

Apr 05, 2026 | Lilly Foundayo vs Novo Oral Wegovy...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/06

Trump's 100% tariff on patented drugs reshapes pharmastrategy—tiered exemptions create winners and losers. Lilly's Foundayo approved; Novo fires back with ORION data showing oral Wegovy's tolerability edge. Plus Biogen-Apellis, Q1's $47B M&A wave, and the first R&Dpipeline contraction in 30 years.visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, pharma tariff, Trump

en-us

00:10:41

Apr 03, 2026 | Trump's 100% Drug Tariffs Reshape...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/04

Trump signs 100% tariffs on imported drugs — but exemptions create a two-tier system reshaping competitive modeling. $25.5B in pharmaM&A in eight days as R&D pipeline shrinks for first time in 30 years. Lilly's Foundayo approved, oral obesity war heats up. ORIC crashes on dose selection.Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, drug tariffs, Section 232, Eli Lilly, Foundayo,

en-us

00:10:16

Apr 02, 2026 | Trump's 100% Drug Tariff Splits...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/03

Trump signs 100% tariff on imported branded drugs—exemptions create pharma haves and have-nots. Lilly's oral obesity pill Foundayo wins FDA approval as analysts project blockbuster launch. Lilly-Centessa ($6.3B) andBiogen-Apellis ($5.6B) deals cap a $25.5B acquisition spree.visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Trump pharma tariff, pharmaceutical tariffs, Eli Lilly, Foundayo,

en-us

00:10:19

Apr 01, 2026 | FDA Approves Lilly's Foundayo Oral...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/04/02

Lilly's Foundayo becomes the first oral GLP-1 approved forobesity in the U.S. — LLY jumps 3.78%. Immunovant's batoclimab misses both Phase 3 endpoints in thyroid eye disease. Plus: Merck-Infinimmune $838M antibody deal, Blackstone's record $6.3B life sciences fund, and the WhiteHouse readies 100% tariffs on imported brand-name drugs.www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Foundayo,

en-us

172 results

Similar Podcasts

Planetterrian Daily

Patrick · Nerra Network

New Books in Science, Technology, and Society

New Books Network

Scifi Friday

Radio Memories Network

The Bio Report

Levine Media Group

Waterlines: How Water Shapes Our World

jaywen